Detalles de la búsqueda
1.
Response to anti-IL17 therapy in inflammatory disease is not strongly impacted by genetic background.
Am J Hum Genet
; 110(10): 1817-1824, 2023 10 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37659414
2.
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Lancet
; 401(10378): 747-761, 2023 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36746171
3.
A framework for longitudinal latent factor modelling of treatment response in clinical trials with applications to Psoriatic Arthritis and Rheumatoid Arthritis.
J Biomed Inform
; 154: 104641, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38642627
4.
Predicting subgroup treatment effects for a new study: Motivations, results and learnings from running a data challenge in a pharmaceutical corporation.
Pharm Stat
; 2024 Feb 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38326967
5.
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.
Ann Rheum Dis
; 82(1): 154-160, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35961761
6.
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
Lancet
; 395(10235): 1496-1505, 2020 05 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32386593
7.
Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials.
J Clin Rheumatol
; 27(6): 239-247, 2021 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32015257
8.
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
N Engl J Med
; 373(26): 2534-48, 2015 Dec 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-26699169
9.
Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: Results from the SUNSHINE and SUNRISE trials.
J Am Acad Dermatol
; 89(6): 1285-1287, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37579844
10.
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.
Ann Rheum Dis
; 76(6): 1070-1077, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27965257
11.
Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
J Drugs Dermatol
; 14(8): 821-33, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26267726
12.
Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1.
Front Immunol
; 11: 561748, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33324394
13.
Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies.
ACR Open Rheumatol
; 2(5): 294-299, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32352653
14.
Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS).
Clin Drug Investig
; 40(3): 269-278, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31983056
15.
Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.
J Rheumatol
; 47(4): 539-547, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31203228
16.
Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study.
Rheumatol Ther
; 5(2): 447-462, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30121827
17.
Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies.
RMD Open
; 4(2): e000749, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30564451
18.
Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
Int J Rheum Dis
; 20(5): 589-596, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28544533
19.
Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1).
Arthritis Rheumatol
; 68(12): 2901-2910, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27390130
Resultados
1 -
19
de 19
1
Próxima >
>>